What is it about?
Although soluble amyloid precursor protein-α (sAPPα) and sAPPβ in cerebrospinal fluid (CSF) are considered as biomarker candidates for early-stage diagnosis of dementia disorders, conflicting data have been reported on their usefulness as diagnostic biomarkers. This article provides a concise overview on this topic.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
By reviewing previous studies and discussing relevant issues, this article is focused on clarifying the value of sAPPs in CSF as biomarkers for dementia disorders.
Perspectives
We hope that this article is useful for better understanding of soluble APPs in CSF as pathologically relevant biomarkers for dementia disorders.
Dr. Wataru Araki
National Center of Neurology and Psychiatry
Read the Original
This page is a summary of: Potential value of soluble APPα
and APPβ
in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives, Neurology and Clinical Neuroscience, June 2018, Wiley,
DOI: 10.1111/ncn3.12195.
You can read the full text:
Contributors
The following have contributed to this page
